One or Two Immune Checkpoint Inhibitors?
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Cell Biology,Oncology
Reference10 articles.
1. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;N. Engl. J. Med.,2019
2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med.,2010
3. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N. Engl. J. Med.,2019
4. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial;Lebbé;J. Clin. Oncol.,2019
5. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥1% by the U.S. Food and Drug Administration;Mountzios;Ann. Oncol.,2019
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mélanomes cutanés malins;Ciblage Thérapeutique en Oncologie;2023
2. Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma;Frontiers in Immunology;2022-08-03
3. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons;Cell Communication and Signaling;2022-04-07
4. Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms;PLOS ONE;2022-03-15
5. The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma;Frontiers in Immunology;2022-01-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3